The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes

Li Sen Liu, Hideho Tanaka, Shinichi Ishii, Jürgen Eckel

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Freshly isolated adult rat ventricular cardiomyocytes have been used to characterize the action profile of the new thiazolidinedione antidiabetic drug MCC-555. Preincubation of cells with the compound (100 μM for 30 min or 10 μM for 2 h) did not modify basal 3-O-methylglucose transport, but produced a marked sensitizing effect (2-to 3-fold increase in insulin action at 3 x 10-11 M insulin) and a further enhancement of maximum insulin action (1.8-fold). MCC-555 did not modulate autophosphorylation of the insulin receptor and tyrosine phosphorylation of insulin receptor substrate- 1 (IRS-1). However, insulin action (10-10 and 10-7 M) on IRS-1- associated phosphatidyl-inositol (PI) 3-kinase activity was enhanced 2-fold in the presence of MCC-555. Association of the p85 adapter subunit of PI 3- kinase to IRS-1 was not modified by the drug. Immunoblotting experiments demonstrated expression of the peroxisomal proliferator-activated receptor- γ in cardiomyocytes reaching about 30% of the abundance observed in adipocytes. The insulin-sensitizing effect of MCC-555 was lost after inhibition of protein synthesis by preincubation of the cells with cycloheximide (1 mM; 30 min). Cardiomyocytes from obese Zucker rats exhibited a completely blunted response of glucose transport at 3 x 10-11 M insulin. MCC-555 ameliorates this insulin resistance, producing a 2-fold stimulation of glucose transport, with maximum insulin action being 1.6-fold higher than that in control cells. This drug effect was paralleled by a significant dephosphorylation of IRS-1 on Ser/Thr. In conclusion, MCC-555 rapidly sensitizes insulin-stimulated cardiac glucose uptake by enhancing insulin signaling resulting from increased intrinsic activity of PI 3-kinase. Acute activation of protein expression leading to a modulation of the Ser/Thr phosphorylation state of signaling proteins such as IRS-1 may be underlying this process. It is suggested that MCC-555 may provide a causal therapy of insulin resistance by targeted action on the defective site in the insulin signaling cascade.

Original languageEnglish
Pages (from-to)4531-4539
Number of pages9
JournalEndocrinology
Volume139
Issue number11
DOIs
Publication statusPublished - 1998
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes. / Liu, Li Sen; Tanaka, Hideho; Ishii, Shinichi; Eckel, Jürgen.

In: Endocrinology, Vol. 139, No. 11, 1998, p. 4531-4539.

Research output: Contribution to journalArticle

Liu, Li Sen ; Tanaka, Hideho ; Ishii, Shinichi ; Eckel, Jürgen. / The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes. In: Endocrinology. 1998 ; Vol. 139, No. 11. pp. 4531-4539.
@article{98e1e719de2f4980a9f52a93ece36e9e,
title = "The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes",
abstract = "Freshly isolated adult rat ventricular cardiomyocytes have been used to characterize the action profile of the new thiazolidinedione antidiabetic drug MCC-555. Preincubation of cells with the compound (100 μM for 30 min or 10 μM for 2 h) did not modify basal 3-O-methylglucose transport, but produced a marked sensitizing effect (2-to 3-fold increase in insulin action at 3 x 10-11 M insulin) and a further enhancement of maximum insulin action (1.8-fold). MCC-555 did not modulate autophosphorylation of the insulin receptor and tyrosine phosphorylation of insulin receptor substrate- 1 (IRS-1). However, insulin action (10-10 and 10-7 M) on IRS-1- associated phosphatidyl-inositol (PI) 3-kinase activity was enhanced 2-fold in the presence of MCC-555. Association of the p85 adapter subunit of PI 3- kinase to IRS-1 was not modified by the drug. Immunoblotting experiments demonstrated expression of the peroxisomal proliferator-activated receptor- γ in cardiomyocytes reaching about 30{\%} of the abundance observed in adipocytes. The insulin-sensitizing effect of MCC-555 was lost after inhibition of protein synthesis by preincubation of the cells with cycloheximide (1 mM; 30 min). Cardiomyocytes from obese Zucker rats exhibited a completely blunted response of glucose transport at 3 x 10-11 M insulin. MCC-555 ameliorates this insulin resistance, producing a 2-fold stimulation of glucose transport, with maximum insulin action being 1.6-fold higher than that in control cells. This drug effect was paralleled by a significant dephosphorylation of IRS-1 on Ser/Thr. In conclusion, MCC-555 rapidly sensitizes insulin-stimulated cardiac glucose uptake by enhancing insulin signaling resulting from increased intrinsic activity of PI 3-kinase. Acute activation of protein expression leading to a modulation of the Ser/Thr phosphorylation state of signaling proteins such as IRS-1 may be underlying this process. It is suggested that MCC-555 may provide a causal therapy of insulin resistance by targeted action on the defective site in the insulin signaling cascade.",
author = "Liu, {Li Sen} and Hideho Tanaka and Shinichi Ishii and J{\"u}rgen Eckel",
year = "1998",
doi = "10.1210/en.139.11.4531",
language = "English",
volume = "139",
pages = "4531--4539",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes

AU - Liu, Li Sen

AU - Tanaka, Hideho

AU - Ishii, Shinichi

AU - Eckel, Jürgen

PY - 1998

Y1 - 1998

N2 - Freshly isolated adult rat ventricular cardiomyocytes have been used to characterize the action profile of the new thiazolidinedione antidiabetic drug MCC-555. Preincubation of cells with the compound (100 μM for 30 min or 10 μM for 2 h) did not modify basal 3-O-methylglucose transport, but produced a marked sensitizing effect (2-to 3-fold increase in insulin action at 3 x 10-11 M insulin) and a further enhancement of maximum insulin action (1.8-fold). MCC-555 did not modulate autophosphorylation of the insulin receptor and tyrosine phosphorylation of insulin receptor substrate- 1 (IRS-1). However, insulin action (10-10 and 10-7 M) on IRS-1- associated phosphatidyl-inositol (PI) 3-kinase activity was enhanced 2-fold in the presence of MCC-555. Association of the p85 adapter subunit of PI 3- kinase to IRS-1 was not modified by the drug. Immunoblotting experiments demonstrated expression of the peroxisomal proliferator-activated receptor- γ in cardiomyocytes reaching about 30% of the abundance observed in adipocytes. The insulin-sensitizing effect of MCC-555 was lost after inhibition of protein synthesis by preincubation of the cells with cycloheximide (1 mM; 30 min). Cardiomyocytes from obese Zucker rats exhibited a completely blunted response of glucose transport at 3 x 10-11 M insulin. MCC-555 ameliorates this insulin resistance, producing a 2-fold stimulation of glucose transport, with maximum insulin action being 1.6-fold higher than that in control cells. This drug effect was paralleled by a significant dephosphorylation of IRS-1 on Ser/Thr. In conclusion, MCC-555 rapidly sensitizes insulin-stimulated cardiac glucose uptake by enhancing insulin signaling resulting from increased intrinsic activity of PI 3-kinase. Acute activation of protein expression leading to a modulation of the Ser/Thr phosphorylation state of signaling proteins such as IRS-1 may be underlying this process. It is suggested that MCC-555 may provide a causal therapy of insulin resistance by targeted action on the defective site in the insulin signaling cascade.

AB - Freshly isolated adult rat ventricular cardiomyocytes have been used to characterize the action profile of the new thiazolidinedione antidiabetic drug MCC-555. Preincubation of cells with the compound (100 μM for 30 min or 10 μM for 2 h) did not modify basal 3-O-methylglucose transport, but produced a marked sensitizing effect (2-to 3-fold increase in insulin action at 3 x 10-11 M insulin) and a further enhancement of maximum insulin action (1.8-fold). MCC-555 did not modulate autophosphorylation of the insulin receptor and tyrosine phosphorylation of insulin receptor substrate- 1 (IRS-1). However, insulin action (10-10 and 10-7 M) on IRS-1- associated phosphatidyl-inositol (PI) 3-kinase activity was enhanced 2-fold in the presence of MCC-555. Association of the p85 adapter subunit of PI 3- kinase to IRS-1 was not modified by the drug. Immunoblotting experiments demonstrated expression of the peroxisomal proliferator-activated receptor- γ in cardiomyocytes reaching about 30% of the abundance observed in adipocytes. The insulin-sensitizing effect of MCC-555 was lost after inhibition of protein synthesis by preincubation of the cells with cycloheximide (1 mM; 30 min). Cardiomyocytes from obese Zucker rats exhibited a completely blunted response of glucose transport at 3 x 10-11 M insulin. MCC-555 ameliorates this insulin resistance, producing a 2-fold stimulation of glucose transport, with maximum insulin action being 1.6-fold higher than that in control cells. This drug effect was paralleled by a significant dephosphorylation of IRS-1 on Ser/Thr. In conclusion, MCC-555 rapidly sensitizes insulin-stimulated cardiac glucose uptake by enhancing insulin signaling resulting from increased intrinsic activity of PI 3-kinase. Acute activation of protein expression leading to a modulation of the Ser/Thr phosphorylation state of signaling proteins such as IRS-1 may be underlying this process. It is suggested that MCC-555 may provide a causal therapy of insulin resistance by targeted action on the defective site in the insulin signaling cascade.

UR - http://www.scopus.com/inward/record.url?scp=0013688753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0013688753&partnerID=8YFLogxK

U2 - 10.1210/en.139.11.4531

DO - 10.1210/en.139.11.4531

M3 - Article

C2 - 9794462

AN - SCOPUS:0013688753

VL - 139

SP - 4531

EP - 4539

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 11

ER -